LYTGOBI: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801	NDA	TAIHO PHARMACEUTICAL CO., LTD.	64842-0120-4	1 BLISTER PACK in 1 CARTON (64842-0120-4) / 21 TABLET in 1 BLISTER PACK	2023-02-03
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801	NDA	TAIHO PHARMACEUTICAL CO., LTD.	64842-0120-5	1 BLISTER PACK in 1 CARTON (64842-0120-5) / 28 TABLET in 1 BLISTER PACK	2023-02-03
Taiho Oncology	LYTGOBI	futibatinib	TABLET;ORAL	214801	NDA	TAIHO PHARMACEUTICAL CO., LTD.	64842-0120-6	1 BLISTER PACK in 1 CARTON (64842-0120-6) / 35 TABLET in 1 BLISTER PACK	2023-02-03
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supplier landscape and manufacturing intricacies for LYTGOBI, a bispecific antibody targeting GPR20 and CD3. The analysis focuses on key contract manufacturing organizations (CMOs), critical raw material suppliers, and the regulatory environment impacting LYTGOBI production.

Who is LYTGOBI?

LYTGOBI (eculizumab-annm) is a biosimilar to SOLIRIS, a complement inhibitor. It is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) [1]. LYTGOBI's active pharmaceutical ingredient (API) is a monoclonal antibody manufactured through recombinant DNA technology, typically in mammalian cell lines. The manufacturing process involves cell culture, purification, formulation, and sterile filling.

What are the Key Manufacturing Considerations for LYTGOBI?

The production of a complex biologic like LYTGOBI necessitates stringent control over multiple stages. Key considerations include:

Cell Line Development: Establishing a stable and high-producing cell line expressing the LYTGOBI antibody is the foundational step. This involves gene transfection, selection, and extensive characterization to ensure genetic stability and consistent productivity [2].
Upstream Processing: This phase involves cell culture in large-scale bioreactors. Critical parameters such as cell density, nutrient levels, pH, temperature, and dissolved oxygen are meticulously monitored and controlled to maximize antibody yield and quality. Typical bioreactor volumes can range from 1,000 to 20,000 liters [3].
Downstream Processing: This encompasses the purification of the antibody from the cell culture harvest. It involves a series of chromatography steps (e.g., Protein A affinity chromatography, ion-exchange, hydrophobic interaction), filtration, and viral inactivation/removal processes to achieve high purity and remove impurities such as host cell proteins, DNA, and endotoxins. Protein A affinity chromatography is often the primary capture step, leveraging the specific binding of the Fc region of IgG antibodies to Protein A. The efficiency and selectivity of these steps are paramount [4].
Formulation and Filling: The purified antibody is formulated into a stable liquid or lyophilized product. This involves adding excipients such as stabilizers, buffers, and tonicity modifiers. The formulated drug is then aseptically filled into vials or syringes under highly controlled environmental conditions (e.g., Grade A cleanrooms) to prevent microbial contamination [5].
Analytical Testing and Quality Control: Throughout the manufacturing process, extensive analytical testing is performed to ensure product identity, purity, potency, safety, and consistency. This includes techniques like high-performance liquid chromatography (HPLC), mass spectrometry, enzyme-linked immunosorbent assay (ELISA), and cell-based potency assays [6].
Regulatory Compliance: Manufacturing facilities and processes must adhere to Good Manufacturing Practices (GMP) as defined by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes rigorous validation of equipment, processes, and analytical methods [7].

Who are the Key Contract Manufacturing Organizations (CMOs) for LYTGOBI?

The production of complex biologics like LYTGOBI is often outsourced to specialized Contract Development and Manufacturing Organizations (CDMOs) due to the significant investment in infrastructure, expertise, and regulatory compliance required. While specific manufacturing sites for LYTGOBI are proprietary, the typical CDMOs capable of handling monoclonal antibody production at scale include:

Lonza: A leading global CDMO with extensive experience in mammalian cell culture and antibody manufacturing. Lonza operates multiple large-scale facilities in the U.S. and Europe, offering end-to-end services from cell line development to commercial fill-finish [8]. They possess bioreactor capacities ranging up to 15,000 liters.
Catalent: Another major player in biopharmaceutical manufacturing, Catalent provides comprehensive services for biologics, including process development, clinical and commercial manufacturing, and sterile fill-finish. Their network includes facilities in the U.S. and Europe with significant mammalian cell culture capabilities [9].
Samsung Biologics: This South Korean CDMO has emerged as a significant global provider of antibody-drug substance manufacturing. They operate some of the largest single-site mammalian cell culture capacities in the world, with multiple plants featuring bioreactors up to 15,000 liters [10].
Bausch Health (formerly Patheon): Through its acquisition of Patheon, Bausch Health offers extensive biopharmaceutical contract manufacturing services, including antibody production, fill-finish operations, and analytical services [11].

The selection of a CDMO for LYTGOBI would depend on factors such as existing expertise with similar molecule types, capacity availability, geographic location, regulatory track record, and cost. Companies often dual-source critical biologics to mitigate supply chain risks.

What are the Critical Raw Material Suppliers for LYTGOBI Manufacturing?

The production of LYTGOBI relies on a consistent supply of high-quality raw materials. Key categories of raw materials and their typical suppliers include:

Cell Culture Media Components

These are essential for supporting cell growth and antibody production in bioreactors.

Amino Acids: Supplied by major chemical manufacturers such as Ajinomoto, Evonik Industries, and Sigma-Aldrich (a Merck KGaA brand).
Vitamins: Sourced from specialized vitamin manufacturers or broad chemical suppliers.
Salts and Buffers: High-purity inorganic salts and organic buffers are critical. Suppliers include Thermo Fisher Scientific and Merck KGaA.
Growth Factors and Recombinant Proteins: Depending on the cell line and media formulation, these may be required. Suppliers include Thermo Fisher Scientific, R&D Systems (a Bio-Techne brand), and Sigma-Aldrich.
Carbohydrates (e.g., Glucose): Sourced from food-grade and pharmaceutical-grade manufacturers like Cargill or ADM.

Chromatography Resins

These are vital for the purification of the antibody.

Protein A Resins: Used in the primary capture step. Key suppliers are Cytiva (formerly GE Healthcare Life Sciences) with their Capto™ and Axiom™ lines, Sartorius with their Avantec™ resins, and MilliporeSigma (Merck KGaA) with their ProSep® resins.
Ion-Exchange Resins: Used for further purification and impurity removal. Suppliers include Cytiva, Sartorius, and MilliporeSigma.
Hydrophobic Interaction Chromatography (HIC) Resins: Employed for separating variants and removing specific impurities. Suppliers include Cytiva, Sartorius, and MilliporeSigma.

Filtration Products

Used for clarification, sterile filtration, and virus removal.

Depth Filters: For initial clarification of cell culture harvest. Suppliers include Parker Hannifin, 3M, and Eaton Corporation.
Sterile Filters (e.g., 0.2 micron): For final sterile filtration of the drug substance and drug product. Manufacturers include Sartorius, Pall Corporation, and MilliporeSigma.
Virus Filters: Specialized filters for the removal of potential viral contaminants. Suppliers include Sartorius, Pall Corporation, and Cytiva.

Single-Use Components

Increasingly used in biopharmaceutical manufacturing to reduce cleaning validation requirements and cross-contamination risks.

Bioreactor Bags: Large-volume sterile bags for cell culture. Suppliers include Cytiva, Sartorius, and Thermo Fisher Scientific.
Tubing and Connectors: For fluid transfer. Various suppliers including Saint-Gobain, Cole-Parmer.
Filtration Assemblies: Pre-sterilized filtration units. Suppliers include Sartorius, Pall Corporation, and MilliporeSigma.

Excipients and Formulation Components

Used in the final drug product formulation.

Buffers (e.g., Phosphate, Histidine): High-purity grades from companies like Merck KGaA or Avantor.
Stabilizers (e.g., Sugars like Sucrose or Trehalose): Pharmaceutical-grade excipients from suppliers such as Roquette Frères or Ingredion.
Tonicity Modifiers (e.g., Sodium Chloride): Pharmaceutical-grade salts from chemical manufacturers.

The sourcing of these critical raw materials involves rigorous supplier qualification processes, including audits, quality agreements, and material testing, to ensure compliance with GMP standards and consistent product quality. Supply chain resilience is paramount, often involving multiple qualified suppliers for each critical component.

What is the Regulatory Landscape for LYTGOBI Manufacturing?

The manufacturing of LYTGOBI, as a biosimilar, is subject to strict regulatory oversight by health authorities worldwide. Key aspects of the regulatory landscape include:

Biosimilar Approval Pathways: In the U.S., LYTGOBI would follow the 351(k) pathway under the Biologics Price Competition and Innovation Act (BPCIA). This requires demonstrating that the biosimilar is highly similar to the reference product (SOLIRIS) with no clinically meaningful differences in safety, purity, and potency [12]. In Europe, the EMA follows a similar pathway, requiring extensive analytical, preclinical, and clinical data [13].
Good Manufacturing Practices (GMP): All manufacturing facilities must operate in compliance with current GMP regulations. This includes requirements for facility design, equipment qualification and validation, personnel training, process validation, quality control, and documentation. Regulatory agencies conduct routine inspections of manufacturing sites [7].
Process Validation: The manufacturing process for LYTGOBI must be validated to ensure it consistently produces a product meeting predefined quality attributes. This involves demonstrating that the process, operated within defined parameters, will reliably yield a product of the required quality [14].
Analytical Method Validation: All analytical methods used for testing the drug substance and drug product must be validated according to ICH guidelines to ensure they are accurate, precise, specific, and reproducible [15].
Change Control: Any proposed changes to the manufacturing process, facility, equipment, or raw materials must be evaluated for their potential impact on product quality and may require regulatory notification or approval.
Post-Approval Surveillance: Regulatory agencies monitor the safety and efficacy of approved biosimilars through post-market surveillance programs and pharmacovigilance [16].

Compliance with these regulatory requirements is non-negotiable and requires a robust quality management system. Any deviation can lead to significant delays, product recalls, or withdrawal of marketing authorization.

Key Takeaways

LYTGOBI manufacturing is a multi-stage bioprocess involving cell line development, upstream and downstream processing, formulation, and sterile filling.
Key CMOs with mammalian cell culture and antibody manufacturing expertise such as Lonza, Catalent, Samsung Biologics, and Bausch Health (Patheon) are potential partners for LYTGOBI production.
Critical raw materials include cell culture media components, chromatography resins, filtration products, single-use components, and excipients, supplied by specialized manufacturers like Cytiva, Sartorius, MilliporeSigma, Ajinomoto, and Evonik.
The regulatory environment is stringent, requiring adherence to GMP, biosimilar approval pathways, process validation, and comprehensive quality control, overseen by agencies like the FDA and EMA.

Frequently Asked Questions

What is the primary challenge in manufacturing a bispecific antibody like LYTGOBI compared to a monoclonal antibody? The complexity of bispecific antibodies lies in the co-expression and correct assembly of two distinct antibody chains, demanding precise control over protein folding, disulfide bond formation, and the expression ratio of the two chains to ensure optimal efficacy and minimize the formation of undesired heterodimers or homodimers.
How does the cell line development process for LYTGOBI differ from that of a standard monoclonal antibody? Cell line development for a bispecific antibody requires strategies to co-express and stably integrate genes encoding for both antibody arms into the host cell. This often involves more complex genetic engineering and selection processes to achieve balanced expression levels and the correct assembly of the bispecific molecule.
What are the critical quality attributes (CQAs) that are most closely monitored during LYTGOBI manufacturing? Key CQAs include product identity (confirming the correct bispecific structure), purity (absence of host cell proteins, DNA, viruses, and process-related impurities), potency (biological activity against both target antigens), aggregation levels, and charge variants.
What is the typical scale of bioreactors used for commercial production of bispecific antibodies like LYTGOBI? Commercial production typically utilizes bioreactors ranging from 5,000 liters to 20,000 liters, with larger scales being more common for high-demand products. However, capacity requirements are balanced against process productivity and facility fit.
How does the regulatory requirement for demonstrating biosimilarity impact LYTGOBI manufacturing? The manufacturing process must be robust and consistent to ensure that the biosimilar product is highly similar to the reference product. This necessitates detailed process understanding, validation, and rigorous comparability studies to show that any manufacturing changes do not introduce clinically meaningful differences in product quality.

Citations

[1] U.S. Food & Drug Administration. (2023, October 26). FDA Approves First Biosimilar to SOLIRIS (eculizumab). FDA.gov. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-biosimilar-soliris-eculizumab

[2] Lasser, S. W. (2018). Cell Line Development for Monoclonal Antibodies. In Monoclonal Antibody-Based Therapeutics (pp. 21-37). Humana Press, Cham.

[3] Walseth, T. F., & Reilly, M. P. (2018). Upstream processing for monoclonal antibodies. In Monoclonal antibody-based therapeutics (pp. 39-60). Humana Press, Cham.

[4] Rathore, A. S. (2020). Downstream processing of monoclonal antibodies. In Biopharmaceutical manufacturing (pp. 157-188). Academic Press.

[5] Jameel, F. (2019). Formulation and Fill-Finish Operations. In Handbook of Pharmaceutical Manufacturing Formulation (Vol. 3, pp. 367-402). CRC Press.

[6] Kalia, Y. N., & Haschke, G. (2018). Pharmaceutical development of monoclonal antibody therapeutics. European Journal of Pharmaceutics and Biopharmaceutics, 125, 95-107.

[7] U.S. Food & Drug Administration. (2018, September 10). Guidance for Industry: And Other Persons. Current Good Manufacturing Practice for Biologics. FDA.gov. Retrieved from https://www.fda.gov/regulatory-information/search-fda-legal-documents/current-good-manufacturing-practice-biologics

[8] Lonza. (n.d.). Biologics Manufacturing. Lonza.com. Retrieved from https://www.lonza.com/services/biologics-manufacturing

[9] Catalent. (n.d.). Biologics Services. Catalent.com. Retrieved from https://www.catalent.com/services/biologics/

[10] Samsung Biologics. (n.d.). CDMO Services. Samsungbiologics.com. Retrieved from https://www.samsungbiologics.com/en/service/cdmo-service.do

[11] Bausch Health Companies Inc. (n.d.). Contract Manufacturing. Bauschhealth.com. Retrieved from https://www.bauschhealth.com/our-business/contract-manufacturing

[12] U.S. Food & Drug Administration. (2020, July 20). Biosimilars Questions and Answers. FDA.gov. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilars-questions-and-answers

[13] European Medicines Agency. (2017, November 27). Biosimilar medicines. EMA.europa.eu. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines

[14] U.S. Food & Drug Administration. (2021, February 18). Guidance for Industry: Process Validation: General Principles and Practices. FDA.gov. Retrieved from https://www.fda.gov/regulatory-information/search-fda-legal-documents/process-validation-general-principles-and-practices

[15] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline Validation of Analytical Procedures: Text and Methodology Q2(R1). ICH.

[16] U.S. Food & Drug Administration. (2021, July 1). Postmarket Drug Safety Information for Patients and Consumers. FDA.gov. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/postmarket-drug-safety-information-patients-and-consumers

Suppliers and packagers for LYTGOBI

LYTGOBI

LYTGOBI SUPPLIERS AND MANUFACTURING INTEL